Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
AVEO Pharmaceuticals, Inc. AVEO
$15.00
На 18:00, 12 мая 2023
-6.67%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
0.00000000
-
week52high
15.00
-
week52low
3.07
-
Revenue
38874000
-
P/E TTM
-18
-
Beta
0.00000000
-
EPS
0.00000000
-
Last Dividend
0.00000000
-
Next Earnings Date
13 мар 2023 г. в 11:00
Описание компании
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC, HCC, immunologically cold tumors, and CCA. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; and AstraZeneca PLC. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 12 июл 2021 г. |
| SVB Leerink | Outperform | Outperform | 11 мар 2021 г. |
| SVB Leerink | Outperform | Outperform | 19 янв 2021 г. |
| SVB Leerink | Outperform | 25 ноя 2020 г. | |
| HC Wainwright & Co. | Buy | 25 ноя 2020 г. | |
| Baird | Neutral | Outperform | 19 окт 2022 г. |
| HC Wainwright & Co. | Neutral | Buy | 18 окт 2022 г. |
| SVB Leerink | Market Perform | Outperform | 24 окт 2022 г. |
| JonesTrading | Hold | Buy | 31 окт 2022 г. |
| Stifel | Hold | Buy | 08 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| BATE KENNETH | D | 0 | 22500 | 19 янв 2023 г. |
| BATE KENNETH | D | 375 | 375 | 19 янв 2023 г. |
| Epperly Corinne | D | 0 | 22500 | 19 янв 2023 г. |
| Ferraresso Michael | D | 0 | 220000 | 19 янв 2023 г. |
| Ferraresso Michael | D | 0 | 220000 | 19 янв 2023 г. |
| Ledell Jebediah | D | 0 | 27702 | 19 янв 2023 г. |
| EVNIN ANTHONY B | D | 0 | 22500 | 19 янв 2023 г. |
| EVNIN ANTHONY B | D | 0 | 22500 | 19 янв 2023 г. |
| Lucera Erick | D | 0 | 218800 | 19 янв 2023 г. |
| BAILEY MICHAEL P | D | 0 | 625192 | 19 янв 2023 г. |
Новостная лента
4 Drug Stocks That More Than Doubled This Year
Zacks Investment Research
30 дек 2022 г. в 10:32
We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022.
Are Medical Stocks Lagging AVEO Pharmaceuticals (AVEO) This Year?
Zacks Investment Research
26 дек 2022 г. в 11:17
Here is how AVEO Pharmaceuticals (AVEO) and Merit Medical (MMSI) have performed compared to their sector so far this year.
AVEO Oncology (AVEO): Strong Industry, Solid Earnings Estimate Revisions
Zacks Investment Research
21 ноя 2022 г. в 12:02
AVEO Oncology (AVEO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
What Makes AVEO Pharmaceuticals (AVEO) a Strong Momentum Stock: Buy Now?
Zacks Investment Research
14 ноя 2022 г. в 13:32
Does AVEO Pharmaceuticals (AVEO) have what it takes to be a top stock pick for momentum investors? Let's find out.
AVEO Pharmaceuticals (AVEO) Reports Q3 Loss, Tops Revenue Estimates
Zacks Investment Research
07 ноя 2022 г. в 20:19
AVEO (AVEO) delivered earnings and revenue surprises of 43.75% and 1.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?